Compare AngloGold Ashanti Limited (AU) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Incyte Corporation — how do they compare? AngloGold Ashanti Limited trades at $98.08 (market cap $49.28B), while Incyte Corporation trades at $120.84 (market cap $24.54B). The key difference: AngloGold Ashanti Limited is far larger — about 2× Incyte Corporation's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| AU | INCY | |
|---|---|---|
Market Cap | $49.28B | $24.54B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $129.93 |
52-Week Low | $52.15 | $81.61 |
Enterprise Value | $48.29B | $20.04B |
Dividend Yield | 4.64% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $98.20, up 0.98% today, near its 52-week high. The stock shows strong fundamental momentum with revenue surging to $9.89B in 2025 and net income reaching $2.64B. Analysts maintain a bullish consensus with a $120.33 price target, supported by robust cash flow and a $2B buyback program. Technical indicators are mixed, with moving averages bullish but RSI levels suggesting overbought conditions. Recent news highlights operational strength and institutional accumulation.
Outlook remains positive driven by gold price strength and production growth, but risks include commodity volatility and operational execution. The stock offers value with a P/E of 13.06 and high profitability margins, though overbought technicals may prompt near-term consolidation. Investor sentiment is favorable, but macroeconomic factors could impact performance.
Incyte Corporation (INCY) trades at $120.93, down 0.51% on the day, near its 52-week high. The stock shows strong fundamental momentum with Q2 2026 EPS beating estimates at $3.09 versus $2.15 expected, driven by robust Jakafi and Opzelura sales. Revenue growth accelerated to $5.14 billion in 2025, with net income margin expanding to 27.71%. Technical indicators signal a bullish trend with moving averages supporting upside, while oscillators remain neutral.
Outlook remains positive given raised 2026 revenue guidance and recent EU approval for Opzelura, though risks include competitive pressures and reliance on key products. Analyst consensus is bullish with a $122.82 price target, implying modest upside from current levels amid solid institutional ownership trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
